Entod Pharmaceuticals has announced that it has received final approval from the Drug Controller General of India (DCGI) for its groundbreaking PresVu eye drops. This approval, disclosed during a press conference held today in New Delhi, follows a favorable recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

PresVu eye drops mark a significant milestone as the first product in India specifically developed to reduce reliance on reading glasses for individuals suffering from presbyopia. Presbyopia, an age-related vision condition that generally affects individuals over the age of 40, is characterized by the gradual loss of the eye’s ability to focus on nearby objects, making reading and other close-up tasks increasingly challenging.

Entod Pharmaceuticals’ CEO, Nikkhil K Masurkar, highlighted the significance of the DCGI approval: “This DCGI approval is a major step forward in our mission to transform eye care in India. PresVu is more than just a product; it’s a solution that stands to improve the lives of millions by offering them greater visual independence.”

PresVu utilizes advanced dynamic buffer technology designed to adapt to the pH of tear fluid. This ensures consistent efficacy and safety, making the eye drops suitable for long-term use. The innovative technology is engineered to maintain effectiveness and safety over extended periods, a critical consideration given that presbyopia affects a significant portion of the global population.

According to global estimates, between 1.09 billion and 1.80 billion individuals are affected by presbyopia, highlighting its widespread impact on both personal well-being and economic productivity. As PresVu approaches its commercial launch, Entod Pharmaceuticals remains committed to driving innovation and supporting the ‘Make in India’ initiative, aiming to make advanced eye care treatments accessible to a broader audience.

Entod Pharmaceuticals is renowned for its diverse portfolio, which spans key therapeutic areas including ENT, ophthalmology, pediatrics, and dermatology. The introduction of PresVu underscores the company’s ongoing efforts to lead in the field of pharmaceutical innovation and enhance patient care.

As PresVu readies for market entry, it represents a significant advancement in eye care, promising to offer millions of individuals greater freedom from the dependency on reading glasses and improving their quality of life.